FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeRobert Q. Le, Richard Pazdur, Donna Przepiorka et al.|The Oncologist|2018Cited by 880
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic LeukemiaR. Angelo de Claro, Richard Pazdur, Karen M. McGinn et al.|Clinical Cancer Research|2015Cited by 165
Dose Finding in Late-Phase Drug DevelopmentLei Nie, Rajeshwari Sridhara, R. Angelo de Claro et al.|Therapeutic Innovation & Regulatory Science|2017Cited by 2